Tg Therapeutics Stock Performance
| TGTX Stock | USD 29.43 0.57 1.90% |
The entity owns a Beta (Systematic Risk) of 0.7, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, TG Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding TG Therapeutics is expected to be smaller as well. At this point, TG Therapeutics has a negative expected return of -0.19%. Please make sure to validate TG Therapeutics' total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if TG Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days TG Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.90) | Five Day Return (7.45) | Year To Date Return 0.51 | Ten Year Return 248.7 | All Time Return (86.92) |
Last Split Factor 100:5625 | Last Split Date 2012-04-30 |
1 | Disposition of 803717 shares by Weiss Michael S of TG Therapeutics subject to Rule 16b-3 | 11/05/2025 |
2 | Disposition of 5000 shares by Echelard Yann of TG Therapeutics at 32.57 subject to Rule 16b-3 | 11/24/2025 |
3 | TG Therapeutics What Wall Street Isnt Telling You - Seeking Alpha | 12/30/2025 |
4 | TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | 01/07/2026 |
5 | Acquisition by Power Sean A of 90000 shares of TG Therapeutics subject to Rule 16b-3 | 01/08/2026 |
6 | TG Therapeutics reports Preliminary Q4 results | 01/13/2026 |
7 | TG Therapeutics Inc Nasdaq 100 Etf Biotech Structure | 01/20/2026 |
8 | Assessing TG Therapeutics Valuation After Recent Share Price Weakness And BRIUMVI Growth Assumptions | 01/27/2026 |
9 | Disposition of 30000 shares by Charney Laurence N of TG Therapeutics subject to Rule 16b-3 | 01/28/2026 |
10 | Disposition of 13197 shares by Charney Laurence N of TG Therapeutics subject to Rule 16b-3 | 01/29/2026 |
| Begin Period Cash Flow | 94.2 M | |
| Total Cashflows From Investing Activities | -1 M |
TG Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,369 in TG Therapeutics on November 2, 2025 and sell it today you would lose (426.00) from holding TG Therapeutics or give up 12.64% of portfolio value over 90 days. TG Therapeutics is currently does not generate positive expected returns and assumes 2.4628% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than TGTX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TG Therapeutics Target Price Odds to finish over Current Price
The tendency of TGTX Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 29.43 | 90 days | 29.43 | about 88.6 |
Based on a normal probability distribution, the odds of TG Therapeutics to move above the current price in 90 days from now is about 88.6 (This TG Therapeutics probability density function shows the probability of TGTX Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days TG Therapeutics has a beta of 0.7. This usually implies as returns on the market go up, TG Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding TG Therapeutics will be expected to be much smaller as well. Additionally TG Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. TG Therapeutics Price Density |
| Price |
Predictive Modules for TG Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as TG Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of TG Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
TG Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. TG Therapeutics is not an exception. The market had few large corrections towards the TG Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold TG Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of TG Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 0.70 | |
σ | Overall volatility | 1.51 | |
Ir | Information ratio | -0.08 |
TG Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of TG Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for TG Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| TG Therapeutics generated a negative expected return over the last 90 days | |
| TG Therapeutics currently holds about 195.71 M in cash with (40.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| TG Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 13197 shares by Charney Laurence N of TG Therapeutics subject to Rule 16b-3 |
TG Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of TGTX Stock often depends not only on the future outlook of the current and potential TG Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. TG Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 160.3 M | |
| Cash And Short Term Investments | 311 M |
TG Therapeutics Fundamentals Growth
TGTX Stock prices reflect investors' perceptions of the future prospects and financial health of TG Therapeutics, and TG Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TGTX Stock performance.
| Return On Equity | 1.12 | ||||
| Return On Asset | 0.0798 | ||||
| Profit Margin | 0.84 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 4.88 B | ||||
| Shares Outstanding | 158.76 M | ||||
| Price To Earning | (4.14) X | ||||
| Price To Book | 7.84 X | ||||
| Price To Sales | 8.99 X | ||||
| Revenue | 329 M | ||||
| Gross Profit | 453.93 M | ||||
| EBITDA | 49.9 M | ||||
| Net Income | 23.38 M | ||||
| Cash And Equivalents | 195.71 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 253.72 M | ||||
| Debt To Equity | 0.62 % | ||||
| Current Ratio | 4.68 X | ||||
| Book Value Per Share | 4.26 X | ||||
| Cash Flow From Operations | (40.52 M) | ||||
| Earnings Per Share | 2.77 X | ||||
| Market Capitalization | 4.78 B | ||||
| Total Asset | 577.69 M | ||||
| Retained Earnings | (1.53 B) | ||||
| Working Capital | 475.68 M | ||||
| Current Asset | 71.33 M | ||||
| Current Liabilities | 16.88 M | ||||
About TG Therapeutics Performance
Evaluating TG Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if TG Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TG Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.2 K | 1.1 K | |
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.10 | 0.07 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.12 | 0.13 |
Things to note about TG Therapeutics performance evaluation
Checking the ongoing alerts about TG Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TG Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TG Therapeutics generated a negative expected return over the last 90 days | |
| TG Therapeutics currently holds about 195.71 M in cash with (40.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| TG Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 13197 shares by Charney Laurence N of TG Therapeutics subject to Rule 16b-3 |
- Analyzing TG Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TG Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining TG Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TG Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TG Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TG Therapeutics' stock. These opinions can provide insight into TG Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.